IntraDose injectable gel with cisplatin or methotrexate data

MATX (Menlo Park, Calif) reported data on five esophageal cancer patients in a Phase I/II trial showing palliative benefits on difficulty in swallowing. Incorporation of cisplatin or methotrexate into the gel improved symptoms without systemic toxicity.

Patients initially had dysphagia (difficulty swallowing) scores of 2.6-3.8 on a scale of 0 to 4. After treatment, one patient's dysphagia was relieved completely (a score of 0) and the scores of the remaining four dropped to 0.5. ...